Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
Earlier from Mesoblast
- Ryoncil® Net Revenues Increase for the Quarter to US$30M
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Ryoncil Sales for the Quarter Increase 60% to US$35.1M
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
Later from Mesoblast
- High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
- Ryoncil® Profits Underpinning Substantial Growth Pipeline
- Half Year Report and Accounts (including Appendix 4D)
- Corporate Presentation and Half Year Financial Results
- Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast